Proceedings of the National Academy of Sciences · 2024 · 40 citations · 47 references
PharmacyImmunologyPharmaceuticsDrug DeliveryGene DeliveryNanoparticle Drug DeliveryLipid-based NanoparticlesMaternal-fetal Immune InteractionsMessenger Rna DeliveryNucleic Acid DeliveryPlacental DevelopmentPregnancy ImmunologyInflammation At The Maternal-fetal InterfaceInnate Immune Responses At The Maternal-fetal InterfaceMaternal ToxicityMaternal-fetal ImmunologyMaternal-fetal ToxicityMrna DeliveryMrna Delivery SystemsMrna Lipid Nanoparticles
Treating pregnancy-related disorders is exceptionally challenging because the threat of maternal and/or fetal toxicity discourages the use of existing medications and hinders new drug development. One potential solution is the use of lipid nanoparticle (LNP) RNA therapies, given their proven efficacy, tolerability, and lack of fetal accumulation. Here, we describe LNPs for efficacious mRNA delivery to maternal organs in pregnant mice via several routes of administration. In the placenta, our lead LNP transfected trophoblasts, endothelial cells, and immune cells, with efficacy being structurally dependent on the ionizable lipid polyamine headgroup. Next, we show that LNP-induced maternal inflammatory responses affect mRNA expression in the maternal compartment and hinder neonatal development. Specifically, pro-inflammatory LNP structures and routes of administration curtailed efficacy in maternal lymphoid organs in an IL-1β-dependent manner. Further, immunogenic LNPs provoked the infiltration of adaptive immune cells into the placenta and restricted pup growth after birth. Together, our results provide mechanism-based structural guidance on the design of potent LNPs for safe use during pregnancy.
47
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Lei S. Qi, Matthew H. Larson, Luke A. Gilbert et al. · Cell · 2013 · 5.2K citations · Full text
David Cox, Jonathan S. Gootenberg, Omar O. Abudayyeh et al. · Science · 2017 · 1.8K citations · Full text
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist et al. · Nature · 2020 · 1.7K citations · Full text